Dr. Avadhut Joshi of the Translational Software science team presented the following PGx insights at the University of Florida Precision Medicine Conference in March of 2017. We are happy to share this data with you. We are continuing to learn from the data and will have additional material to share periodically.

In the analysis

TSI reviewed the medication lists of 505,000 de-identified patients submitted through its laboratory network from 2013 to 2017 to identify drug-gene interactions with four important pharmacogenes: CYP2C9, CYP2C19, CYP2D6 and SLCO1B1. Results of the analysis showed that 20 percent of patients had a pharmacogenetics (PGx) profile associated with a severe drug-gene interaction to drugs on their current medication list. An additional 48 percent of patients had a profile that caused a moderate drug-gene interaction. Complete the contact form to receive an email with a copy of the poster. Opt-in to receive periodic updates from Translational Software®.